This episode features excerpts from an interview with Dr Holbrook Kohrt who was leading the way in researching the potential of immune agonists targeting 4-1BB (CD137). It is with great sadness that we must report that since this episode aired, Holbrook Kohrt is no longer with us. He died, aged 38, on February 24, 2016.

Dr Holbrook Kohrt Stanford

In-Memorium Holbrook Kohrt 

Episode Theme

Immune modulators come in two flavors – the much discussed checkpoint inhibitors that we featured in Episode 1 “The Checkpoints Show” are inhibitory and “release the brake,” while immune agonists are stimulatory and help to “step on the gas” and make the immune system more effective.

In addition to introducing the concept of immune agonists, this episode seeks to take our journey forward by discussing how they may be used in combination. You’ll hear again from Dr Tom Gajewski (Chicago), who you may recall from Episode 2 “The Immune Biomarker Show.”

Also featured in Episode 6, is Dr William Pao (Roche) who describes the company’s T cell focused strategy and how they segment new products into T cell effectors, modulators and generators.

You may recall hearing a “vignette” or mini-interview with Dr Pao in Episode 3 “ASCO Lung Cancer Show.”

Dr William Pao Roche

There’s also an excerpt from an interview with Prof Tom Powles (Barts) on checkpoint inhibitors in bladder cancer.  Potentially practice-changing data for atezolizumab in metastatic bladder cancer and nivolumab in renal cell carcinoma is expected at the forthcoming European Cancer Congress.

Additional Resources

The interviews on the podcast were originally published on Biotech Strategy Blog (subscription required) and are excerpted on the podcast with permission.

Holbrook Kohrt: “Holbrook Kohrt leads the way in Targeting CD137”

William Pao: “Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?”

Tom Powles: “Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment”

Podcast Music

The music in this podcast episode is by electric violinist and composer David Schulman from his album Quiet Life Motel.

Podcast Sponsorship

Genentech Corporate LogoGenentech sponsored this episode of Novel Targets – we’re grateful for their support!

Dr Deepak Sampath (Genentech) at 2013 EORTC-NCI-AACR Molecular Targets meeting

Instead of a formal advertisement or reading a corporate message, we offer listeners mini interviews or vignettes with scientists and physicians to showcase their research.

In this episode, we featured Dr Deepak Sampath from Genentech who talked about his research into the combination of obinutuzumab with venetoclax.

This is an excerpt of an interview we did at the 2013 EORTC-NCI-AACR Molecular Targets meeting in Boston where Dr Sampath presented a poster.

You can find a transcript of the full interview on Biotech Strategy Blog (sub  req’d): “Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath.”

 




© Blue Ice Publishing LLC. All Rights Reserved.

error: Please do not copy copyrighted content